Celularity CEO Comments on Centers for Medicare & Medicaid Services Withdrawal of Skin Substitute Local Coverage Determinations
While Celularity’s Biovance® and Biovance 3L products remained eligible for Medicare coverage…
Global study targets dengue as disease threatens nearly half the world’s population
LISMORE, Australia, Dec. 18, 2025 /PRNewswire/ -- Thousands of dengue forecasting models…
Greening Learning Spaces in Crisis Settings
Education Cannot Wait and Save the Children announce partnership, in consortium with…
Total Investment of Approx. USD 11.6 Million in TB and NTD R&D Projects With Partners Including Fujifilm, Stop TB Partnership, and the Ohio State University
TOKYO, Oct. 29, 2025 /PRNewswire/ -- The Global Health Innovative Technology (GHIT) Fund announced…